<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900743</url>
  </required_header>
  <id_info>
    <org_study_id>REGO-SARC-1214</org_study_id>
    <secondary_id>2012-005743-24</secondary_id>
    <nct_id>NCT01900743</nct_id>
  </id_info>
  <brief_title>Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma</brief_title>
  <acronym>REGO-SARC</acronym>
  <official_title>Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international (France, Austria and Germany), randomized, double-blind,&#xD;
      placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in&#xD;
      patients with histologically proven metastatic and/or unresectable Soft Tissue Sarcoma (STS)&#xD;
      after failure or intolerance to doxorubicin (or other anthracycline).&#xD;
&#xD;
      Five cohorts will be defined:&#xD;
&#xD;
      Cohort A: Liposarcoma Cohort B: Leiomyosarcoma Cohort C: Synovial sarcoma Cohort D: other&#xD;
      sarcomas (see Appendix C) Cohort E: Leiomyosarcoma, Synovial sarcoma and other sarcomas&#xD;
      listed in Appendix C previously treated with pazopanib Approximately 226 patients who meet&#xD;
      the eligibility criteria will be randomly assigned in a 1:1 ratio to one of the treatment&#xD;
      groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard of care for metastatic soft tissue sarcoma is doxorubicin +/- ifosfamide. After&#xD;
      failure or intolerance to doxorubicin, there is no standard of care. In Europe, two are&#xD;
      currently approved for the treatment of soft tissue sarcoma after failure/intolerance to&#xD;
      doxorubicin: trabectedin (Yondelis®) for all histological subtype and pazopanib (Votrient ®)&#xD;
      for all subtypes excluding liposarcomas. Nevertheless, none of these drugs improve the&#xD;
      overall survival over placebo.&#xD;
&#xD;
      The study is composed of 3 periods:&#xD;
&#xD;
        1. A Screening Period,&#xD;
&#xD;
        2. A Treatment Period,&#xD;
&#xD;
        3. And a Survival Follow-up Period. Patients randomized to be treated with regorafenib will&#xD;
           receive the treatment orally for 3 weeks of every 4 week (28 days) cycle (ie, 3 weeks&#xD;
           on/1 week off).&#xD;
&#xD;
      Patients randomized to the placebo arm will be treated for 3 weeks of every 4 weeks cycle&#xD;
      (ie, 3 weeks on/1 week off).&#xD;
&#xD;
      In addition to the regorafenib and placebo treatments, patients will receive best supportive&#xD;
      care. Best supportive care includes any method to preserve the comfort and dignity of the&#xD;
      patients and excludes any disease-specific anti-neoplastic therapy such as any kinase&#xD;
      inhibitor,chemotherapy, radiation therapy, or surgical intervention.&#xD;
&#xD;
      Patients receiving placebo, who experience disease progression may be offered open-label&#xD;
      regorafenib(cross-over option).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2013</start_date>
  <completion_date type="Actual">September 16, 2020</completion_date>
  <primary_completion_date type="Actual">September 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-Free Survival will be measured from the date of randomization until the date of radiological progression or death (if death occurs before progression).&#xD;
Progression-free rate at 3 and 6 months (PFR-3 and PFR-6), time to progression, response rate and duration of response, overall survival according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth modulation index</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Growth modulation index in patients receiving regorafenib after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI-CTC AE V4.0.</measure>
    <time_frame>Baseline, every 4 weeks, up to the end of study</time_frame>
    <description>The monitoring of the toxicity of the regorafenib which can have a liver toxicity for exemple.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free rate at 3 and 6 months (PFR-3 and PFR-6)</measure>
    <time_frame>At month 3 and at month 6</time_frame>
    <description>According to the RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>According to the RECIST 1.1 Every 4 weeks, Up to 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>the proportion of patients with the best overall tumor response of partial response (PR) or complete response (CR) according to RECIST 1.1 guidelines that is achieved during treatment or within 30 days after termination of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>the number of days from the date of first documented objective response of PR or CR, whichever is noted earlier, to first disease progression or death before progression. Patients without progression or death before progression at the time of analysis will be censored at the date of their last tumor assessment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Potential predictive factors for regorafenib response.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The monitoring of the factors which can induce a regorafenib response (Formalin fixed, paraffin embedded (FFPE) or fresh frozen tissue samples collected either from the primary tumor or from metastatic sites, or both will be analyzed)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histological documentation of soft tissue sarcoma (including uterus)with available&#xD;
             Formalin Fixed Paraffin Embedded (FFPE) blocks. Eligible soft tissue sarcomas are&#xD;
             non-adipocytic soft tissue sarcomas&#xD;
&#xD;
          -  Prior treatment with doxorubicin or other anthracycline. Moreover, patients eligible&#xD;
             in the Cohort E must have received pazopanib&#xD;
&#xD;
          -  Metastatic disease not amenable to surgical resection with curative intent&#xD;
&#xD;
          -  Documentation of progression within the last 6 months&#xD;
&#xD;
          -  Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT&#xD;
             scan as defined by RECIST 1.1.&#xD;
&#xD;
          -  Performance status ≤1(ECOG)&#xD;
&#xD;
          -  Life expectancy ≤ 3 months&#xD;
&#xD;
          -  Adequate bone marrow, renal, and hepatic function:&#xD;
&#xD;
          -  INR/PTT ≤1.5 x ULN Patients who are therapeutically treated with an agent such as&#xD;
             warfarin or heparin will be allowed to participate provided that no prior evidence of&#xD;
             underlying abnormality in coagulation parameters exists. Close monitoring will be&#xD;
             performed until INR/PTT is stable.&#xD;
&#xD;
          -  Women of childbearing potential and male patients must agree to use adequate&#xD;
             contraception for the duration of study participation and up to 3 months following&#xD;
             completion of therapy.&#xD;
&#xD;
          -  Recovery to NCI-CTCAE v4.0 Grade 0 or 1 level or recovery to baseline preceding the&#xD;
             prior treatment from any previous drug/procedure related toxicity (except alopecia,&#xD;
             anemia, and hypothyroidism).&#xD;
&#xD;
          -  In the assessment of the investigator, patient is able to comply with study&#xD;
             requirements&#xD;
&#xD;
          -  Signed, IRB-approved written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 3 lines of systemic treatment for metastatic sarcoma&#xD;
&#xD;
          -  Histological subtypes listed in Appendix C (especially GIST, osseous sarcoma,&#xD;
             embryonal or alveolar rhabdomyosarcoma). Patients with liposarcoma are not eligible in&#xD;
             the cohort E&#xD;
&#xD;
          -  Primary bone sarcoma&#xD;
&#xD;
          -  Prior treatment with regorafenib&#xD;
&#xD;
          -  Known history of or concomitant malignancy likely to affect life expectancy in the&#xD;
             judgment of the investigator&#xD;
&#xD;
          -  Pregnant or breastfeeding patients. Women of childbearing potential must have a&#xD;
             pregnancy test performed before start of treatment&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             before start of treatment&#xD;
&#xD;
          -  Active cardiac disease including any of the following: Congestive heart failure (NYHA)&#xD;
             ≥Class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within&#xD;
             the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy (beta&#xD;
             blockers or digoxin are permitted)&#xD;
&#xD;
          -  Uncontrolled hypertension (SBP &gt;150 mmHg or diastolic pressure &gt;90 mmHg despite&#xD;
             optimal medical management)&#xD;
&#xD;
          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism&#xD;
             (within the last 6 months)&#xD;
&#xD;
          -  Ongoing infection &gt;Grade 2 according to NCI-CTCAE v4.0&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known history of chronic hepatitis B or C&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event &gt; Grade 3&#xD;
             within 4 weeks of start of treatment&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
          -  Dehydration according to NCI-CTC v 4.0 Grade &gt;1&#xD;
&#xD;
          -  Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation, including lactose&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Inability to swallow, malabsorption condition&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PENEL, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas BRODOWICZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AKH-Wien - Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin I</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH-Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre GF Leclercq</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth (ICL)</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>32052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Regorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

